El Dorado Hills, CA - EMED Technologies Corporation is pleased to announce it will be moving into a new facility in El Dorado Hills, California in May 2010. The new corporate office is intended to its world headquarters where the following principal activities will be conducted:  Research and Development; Engineering conceptual design and development; Intellectual Property management; Sales, Marketing and Clinical support services to domestic and international distributors; and Corporate Management of its North America and European operations.

Some of the company’s alternate sites will be consolidated in this Northern California facility over the next few months. The new facility will also serve as a place for operation to new acquisitions the company has been focusing on as part of its plan to implement its vertical and horizontal integration.

EMED develops manufactures and markets leading-edge medical products. Its focus is to partner with inventors, clinicians, marketers and industry leaders to develop optimal medical technology paradigms that can offer patients and clinicians advantages over less efficacious technologies.

The company has been capitalizing most of its profits over the last five years to establish a sound base of operation and to foster a healthy business model. It has made efficient use of its resources to maximize their allocation to Research and Development activities with particular emphasis on novel medical device concepts and potential breakthrough technologies.

EMED has traditionally been an innovator in Infusion Therapy technologies:  and is the current market segment leader providing specialty infusion sets used for the administration of Immunoglobulin to Immune deficient patients. The company plans to launch three new devices within the infusion technology product group (a non-electric ambulatory infusion pump, safety subcutaneous sets and safety implanted-port-access sets) starting in the fourth quarter of 2010. These patented new products simplify ambulatory infusion paradigms and they important appeal to domestic and international markets.

EMED acquired Innovamed in October of 2008.  Innovamed had developed Functional Electrical Stimulation devices for over a decade. Its founder: Ing. Ernst Czadilek -an Austrian inventor-, developed “detrusan” a highly efficacious system for the cure of urinary incontinence (UI). For the last two years, EMED has been enhancing this Urinary Continence technology and preparing a Europe-wide marketing program. Innovamed R&D support laboratory will be moved to the new Northern California facility where the European launch of this product will be managed and supported.

In addition to continuing to capitalize its profits, EMED has been actively working with various private and institutional investors to establish adequate mechanisms to allocate various rounds of capital over the next few years to fund both Research & Development and Acquisitions.